Key Takeaways
- • Strategy has raised an estimated $50 billion in new equity over approximately 18 months while paying roughly $274 million in underwriting fees to the same Wall Street banks that maintain bullish analyst ratings on the stock.
- • Strategy commands a consensus "Strong Buy" rating with an average analyst price target implying 155% upside from recent prices—nearly double the implied upside for any other large-cap U.S. stock—despite being the single largest equity issuer on any U.S. exchange.
- • Major Wall Street analysts covering Strategy include Bernstein (Outperform, $600 target), TD Cowen (Buy, $440 target), Cantor Fitzgerald (Overweight), B. Riley Securities (Buy, initiated March 2026), and Benchmark (highest target at $705), while only Wells Fargo maintains a bearish $54 target.
- • The structural overlap between the banks publishing bullish research and those collecting substantial fees from Strategy's equity issuances creates a significant conflict of interest, raising questions about whether analyst enthusiasm is financially incentivized rather than fundamentally justified.
Summary
Wall Street maintains exceptionally bullish coverage of Strategy despite a structural conflict of interest that warrants scrutiny from institutional investors. The company has emerged as the single largest new stock issuer across all U.S. exchanges, having raised approximately $50 billion in equity capital over an 18-month period while simultaneously paying roughly $274 million in underwriting and advisory fees to the same financial institutions that publish research on the stock.
Strategy's analyst consensus reflects this enthusiasm: the stock carries a "Strong Buy" rating with an average price target implying 155% upside from recent trading levels. This represents nearly double the median upside for any other large-cap name in America, an outlier valuation that demands examination. The breadth of bullish coverage is noteworthy, with Bernstein maintaining an Outperform rating (previously $600 target), TD Cowen issuing a Buy (at $440), Cantor Fitzgerald an Overweight, and Benchmark setting the street-high target of $705. B. Riley Securities initiated coverage with a Buy rating in March 2026. Only Wells Fargo has published a materially bearish call, with a $54 target that stands conspicuously isolated against the broader consensus.
The critical issue is not whether any party has violated securities law—the article explicitly notes that no current misconduct has occurred—but rather whether the financial incentive structure has become so tightly interwoven that analyst objectivity may be compromised. The banks collecting substantial fees from Strategy's continuous equity issuance pipeline are the same entities setting and publishing the bullish price targets that support continued capital raises. This creates a feedback loop: higher analyst targets may sustain stock valuations that facilitate easier equity issuance, which in turn generates additional fees. Whether this arrangement represents an "unjustified" level of optimism, as the source suggests, is a question institutional investors should evaluate independently when assessing the stock's risk-return profile and the reliability of consensus research.
Strategy's analyst consensus reflects this enthusiasm: the stock carries a "Strong Buy" rating with an average price target implying 155% upside from recent trading levels. This represents nearly double the median upside for any other large-cap name in America, an outlier valuation that demands examination. The breadth of bullish coverage is noteworthy, with Bernstein maintaining an Outperform rating (previously $600 target), TD Cowen issuing a Buy (at $440), Cantor Fitzgerald an Overweight, and Benchmark setting the street-high target of $705. B. Riley Securities initiated coverage with a Buy rating in March 2026. Only Wells Fargo has published a materially bearish call, with a $54 target that stands conspicuously isolated against the broader consensus.
The critical issue is not whether any party has violated securities law—the article explicitly notes that no current misconduct has occurred—but rather whether the financial incentive structure has become so tightly interwoven that analyst objectivity may be compromised. The banks collecting substantial fees from Strategy's continuous equity issuance pipeline are the same entities setting and publishing the bullish price targets that support continued capital raises. This creates a feedback loop: higher analyst targets may sustain stock valuations that facilitate easier equity issuance, which in turn generates additional fees. Whether this arrangement represents an "unjustified" level of optimism, as the source suggests, is a question institutional investors should evaluate independently when assessing the stock's risk-return profile and the reliability of consensus research.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.